Published in Lancet on November 16, 1991
Synthesis of lipopolysaccharide O side chains by Pseudomonas aeruginosa PAO1 requires the enzyme phosphomannomutase. J Bacteriol (1993) 1.50
Microbiology of cystic fibrosis lung infections: themes and issues. J R Soc Med (1993) 1.46
A murine model of chronic mucosal colonization by Pseudomonas aeruginosa. Infect Immun (1992) 1.41
A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci U S A (2007) 1.27
Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats. Infect Immun (1994) 1.23
Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection. Infect Immun (1994) 1.07
Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob Agents Chemother (2010) 0.98
Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection. Infect Immun (2010) 0.97
Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P. aeruginosa-pulsed dendritic cells. Infect Immun (2001) 0.95
Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06. Infect Immun (1994) 0.87
Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts. Drugs (1993) 0.82
Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clin Exp Immunol (2006) 0.79
Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clin Exp Immunol (2005) 0.75
CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med (2000) 6.06
Isolation and characterization of Pseudomonas aeruginosa PAO mutant that produces altered elastase. J Bacteriol (1980) 5.74
Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Vaccine (1998) 3.22
Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats. Infect Immun (1982) 2.76
Role of lipopolysaccharide in virulence of Pseudomonas aeruginosa. Infect Immun (1984) 2.39
Dexamethasone therapy for bacterial meningitis in children. Swiss Meningitis Study Group. Lancet (1993) 2.34
Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science (1988) 2.09
Effect of streptomycin administration on colonization resistance to Salmonella typhimurium in mice. Infect Immun (1985) 1.99
Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis (1992) 1.94
Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae. J Infect Dis (1993) 1.93
Seroepidemiology of Klebsiella bacteremic isolates and implications for vaccine development. J Clin Microbiol (1986) 1.92
Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine (1990) 1.87
Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide. Infect Immun (1983) 1.79
Synthesis and chemical properties of monomers and polymers containing 7-methylguanine and an investigation of their substrate or template properties for bacterial deoxyribonucleic acid or ribonucleic acid polymerases. Biochemistry (1970) 1.74
Protective role of intestinal flora against infection with Pseudomonas aeruginosa in mice: influence of antibiotics on colonization resistance. Infect Immun (1985) 1.74
Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Pediatr (1995) 1.73
Factors responsible for increased susceptibility of mice to intestinal colonization after treatment with streptomycin. Infect Immun (1986) 1.71
Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine (2000) 1.67
A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med (1990) 1.63
Immunity in experimental salmonellosis. II. Basis for the avirulence and protective capacity of gal E mutants of Salmonella typhimurium. Infect Immun (1971) 1.62
Regulation of toxinogenesis in Corynebacterium diphtheriae: mutations in the bacterial genome that alter the effects of iron on toxin production. J Bacteriol (1983) 1.60
Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice. Infect Immun (1983) 1.57
Genetic and biochemical evidence for a siderophore-dependent iron transport system in Corynebacterium diphtheriae. Infect Immun (1984) 1.53
Isolation and characterization of a Pseudomonas aeruginosa mutant producing a nontoxic, immunologically crossreactive toxin A protein. Proc Natl Acad Sci U S A (1980) 1.50
Immunogenicity of new virosome influenza vaccine in elderly people. Lancet (1994) 1.48
A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br J Dermatol (2015) 1.46
Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model. Infect Immun (1983) 1.45
Effect of race and blood group on the immune response to bacterial polysaccharide and conjugate vaccines. Lancet (1990) 1.41
[Aseptic meningitis in pediatrics]. Schweiz Med Wochenschr (1991) 1.40
Hospital management. Br Med J (1967) 1.39
Experimental Klebsiella pneumoniae burn wound sepsis: role of capsular polysaccharide. Infect Immun (1984) 1.39
Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide. Infect Immun (1984) 1.38
Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun (1992) 1.35
Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Invest (1987) 1.33
Immunochemical studies of diphtherial toxin and related nontoxic mutant proteins. Infect Immun (1980) 1.32
Preparation of a purified antigenic cholera toxoid. Infect Immun (1976) 1.31
Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect Immun (1999) 1.31
Purification of Pseudomonas aeruginosa exoenzyme S. Infect Immun (1987) 1.28
Progress in immunization against Klebsiella infections. Eur J Clin Microbiol (1983) 1.22
Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group. J Infect Dis (1996) 1.21
Procholeragenoid: a safe and effective antigen for oral immunization against experimental cholera. Infect Immun (1983) 1.19
Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans. J Infect Dis (1986) 1.19
Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med (1997) 1.18
Alteration of pulmonary structure by Pseudomonas aeruginosa exoenzyme S. J Med Microbiol (1988) 1.15
Protection against fatal Klebsiella pneumoniae burn wound sepsis by passive transfer of anticapsular polysaccharide. Infect Immun (1984) 1.14
Purification and vaccine potential of Klebsiella capsular polysaccharides. Infect Immun (1985) 1.14
Production of alkaline protease by Pseudomonas aeruginosa. J Clin Microbiol (1980) 1.12
Development of an enzyme-linked immunosorbent assay for studying Vibrio cholerae cell surface antigens. J Clin Microbiol (1982) 1.12
Cell-associated hemagglutinin-deficient mutant of Vibrio cholerae. Infect Immun (1987) 1.12
Long-term cimetidine in children with cystic fibrosis: a randomized double-blind study. Pediatr Res (1984) 1.11
Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine. Infect Immun (1986) 1.10
Protection against colibacillosis in neonatal piglets by immunization of dams with procholeragenoid. Infect Immun (1982) 1.10
Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats. Am J Respir Crit Care Med (1995) 1.10
Immunization against fatal experimental Klebsiella pneumoniae pneumonia. Infect Immun (1986) 1.09
Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection. Infect Immun (1994) 1.07
Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin. J Immunol (1993) 1.06
Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates. Infect Immun (1987) 1.06
Monoclonal antibodies that define neutralizing epitopes of pertussis toxin: conformational dependence and epitope mapping. Infect Immun (1989) 1.05
Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans. J Infect Dis (1985) 1.05
Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A. Infect Immun (1992) 1.05
Sinus bradycardia following treatment with hydergine for cerebrovascular insufficiency. Br Med J (1975) 1.04
Monoclonal antibody against Klebsiella capsular polysaccharide reduces severity and hematogenic spread of experimental Klebsiella pneumoniae pneumonia. Infect Immun (1992) 1.04
Prevention of fatal experimental burn-wound sepsis due to Klebsiella pneumoniae KP1-O by immunization with homologous capsular polysaccharide. J Infect Dis (1984) 1.03
A polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Antibiot Chemother (1971) (1987) 1.00
Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously. Vaccine (1994) 1.00
Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect Immun (1997) 0.99
Antigenicity of cholera toxoid in humans. J Infect Dis (1977) 0.99
Immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharides and exotoxin A in patients with cystic fibrosis or bacteremia. Eur J Clin Microbiol Infect Dis (1993) 0.99
Extension of the volunteer challenge model to study South American cholera in a population of volunteers predominantly with blood group antigen O. Trans R Soc Trop Med Hyg (1995) 0.97
Monoclonal antibodies to human type IV collagen: useful reagents to demonstrate the heterotrimeric nature of the molecule. Proc Natl Acad Sci U S A (1984) 0.97
Effect of formalin toxoiding on Pseudomonas aeruginosa toxin A: biological, chemical, and immunochemical studies. Infect Immun (1981) 0.96